ORKA (Oruka Therapeutics) EPS (Basic) : $ (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics EPS (Basic)?

Oruka Therapeutics's basic earnings per share (Basic EPS) for the six months ended in Mar. 2024 was $0.00. Oruka Therapeutics does not have enough years/quarters to calculate its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2024.

Oruka Therapeutics's EPS (Diluted) for the six months ended in Mar. 2024 was $0.00. Oruka Therapeutics does not have enough years/quarters to calculate its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024.

Oruka Therapeutics's EPS without NRI for the six months ended in Mar. 2024 was $0.00. Oruka Therapeutics does not have enough years/quarters to calculate its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Oruka Therapeutics EPS (Basic) Historical Data

The historical data trend for Oruka Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics EPS (Basic) Chart

Oruka Therapeutics Annual Data

Trend

Dec24

EPS (Basic)

Oruka Therapeutics Semi-Annual Data
	Mar24
EPS (Basic)	-

Oruka Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Oruka Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(0	-	0)	/	0
	=

Oruka Therapeutics's Basic EPS for the quarter that ended in Mar. 2024 is calculated as

Basic EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(0	-	0)	/	0
	=

Oruka Therapeutics (NAS:ORKA) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Oruka Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (NAS:ORKA) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

HQ1:Germany

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.